Literature DB >> 18562509

Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.

P Jung1, A Beyerle, U Ziemann.   

Abstract

In 37 patients with early relapsing-remitting multiple sclerosis (RRMS), a multimodal EP score (mEPS) and clinical scores (Expanded Disability Status Scale (EDSS) and multiple sclerosis functional composite (MSFC)) were obtained prospectively over 24 months. Changes in mEPS correlated with changes in EDSS (Spearman's rho = 0.69, p < 0.0001) and MSFC (rho = -0.41, p < 0.02). Patients with relevant EDSS progression (n = 7) showed stronger mEPS deterioration than clinically stable patients (10.8 +/- 3.2 versus 1.3 +/- 0.8, p < 0.005). Baseline mEPS was not significantly correlated with baseline EDSS but with EDSS after 24 months (rho = 0.39, p < 0.02). The data suggest that serial mEPS measure and moderately predict clinically relevant disease activity in the therapeutically most relevant early stage of RRMS.

Entities:  

Mesh:

Year:  2008        PMID: 18562509     DOI: 10.1177/1352458507085758

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

Review 1.  Neurophysiological markers.

Authors:  Letizia Leocani; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

Review 2.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

4.  Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis.

Authors:  N Margaritella; L Mendozzi; M Garegnani; E Colicino; E Gilardi; L Deleonardis; F Tronci; L Pugnetti
Journal:  Neurol Sci       Date:  2011-11-27       Impact factor: 3.307

5.  Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.

Authors:  Xavier Giffroy; Nathalie Maes; Adelin Albert; Pierre Maquet; Jean-Michel Crielaard; Dominique Dive
Journal:  BMC Neurol       Date:  2016-06-01       Impact factor: 2.474

Review 6.  A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS.

Authors:  Martin Hardmeier; Letizia Leocani; Peter Fuhr
Journal:  Mult Scler       Date:  2017-05-08       Impact factor: 6.312

7.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

8.  Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).

Authors:  Ralf Gold; Gavin Giovannoni; J Theodore Phillips; Robert J Fox; Annie Zhang; Leslie Meltzer; Nuwan C Kurukulasuriya
Journal:  Mult Scler       Date:  2014-07-02       Impact factor: 6.312

9.  The effect of transcutaneous spinal direct current stimulation on corticospinal excitability in chronic incomplete spinal cord injury.

Authors:  Elizabeth Salmon Powell; Cheryl Carrico; Emily Salyers; Philip M Westgate; Lumy Sawaki
Journal:  NeuroRehabilitation       Date:  2018       Impact factor: 2.138

10.  Cortical Excitability and Interhemispheric Connectivity in Early Relapsing-Remitting Multiple Sclerosis Studied With TMS-EEG.

Authors:  Carl M Zipser; Isabella Premoli; Paolo Belardinelli; Nazareth Castellanos; Davide Rivolta; Tonio Heidegger; Florian Müller-Dahlhaus; Ulf Ziemann
Journal:  Front Neurosci       Date:  2018-06-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.